Evidence map›Paper›PMID 37761830›Full record

ArticleGenes2023

Whole-Exome Sequencing Reveals High Mutational Concordance between Primary and Matched Recurrent Triple-Negative Breast Cancers.

Jaspreet Kaur, Darshan S Chandrashekar, Zsuzsanna Varga, Bettina Sobottka, Emiel Janssen, Khanjan Gandhi, Jeanne Kowalski, Umay Kiraz, Sooryanarayana Varambally, Ritu Aneja

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Jaspreet KaurDepartment of Biology, Georgia State University, Atlanta, GA 30303, USA.
Darshan S ChandrashekarDepartment of Pathology-Molecular and Cellular, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-4295-9127
Zsuzsanna VargaDepartment of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-2855-983X
Bettina SobottkaDepartment of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.
Emiel JanssenDepartment of Pathology, Stavanger University Hospital, Health Stavanger HF, 4068 Stavanger, Norway.ORCID 0000-0002-7760-5396
Khanjan GandhiWinship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
Jeanne KowalskiLivestrong Cancer Institutes, Dell Medical School, The University of Texas at Austin, Austin, TX 78712, USA.ORCID 0000-0003-3458-3024
Umay KirazDepartment of Pathology, Stavanger University Hospital, Health Stavanger HF, 4068 Stavanger, Norway.ORCID 0000-0002-6721-4877
Sooryanarayana VaramballyDepartment of Pathology-Molecular and Cellular, University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0002-2277-1127
Ritu AnejaDepartment of Biology, Georgia State University, Atlanta, GA 30303, USA.
Georgia State University · USStavanger University Hospital · NOUniversity Hospital of Zurich · CHUniversity of Alabama at Birmingham · USEmory University · USLivestrong Foundation · US

Funding

HSET as a racial disparity biomarker for TNBC patientsR01CA239120 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANEJA, RITU · 2019 to 2024
$3.0M
NCI NIH HHS R01 CA239120
6 · The paper itself

Abstract

purposeTriple-negative breast cancer (TNBC) is a molecularly complex and heterogeneous breast cancer subtype with distinct biological features and clinical behavior. Although TNBC is associated with an increased risk of metastasis and recurrence, the molecular mechanisms underlying TNBC metastasis remain unclear. We performed whole-exome sequencing (WES) analysis of primary TNBC and paired recurrent tumors to investigate the genetic profile of TNBC.

methodsGenomic DNA extracted from 35 formalin-fixed paraffin-embedded tissue samples from 26 TNBC patients was subjected to WES. Of these, 15 were primary tumors that did not have recurrence, and 11 were primary tumors that had recurrence (nine paired primary and recurrent tumors). Tumors were analyzed for single-nucleotide variants and insertions/deletions.

resultsThe tumor mutational burden (TMB) was 7.6 variants/megabase in primary tumors that recurred (

conclusionsWe found similar mutational profiles between primary and paired recurrent tumors, suggesting that genomic features may be retained during local recurrence.

Indexed as

Biomarkers, TumorMutationNeoplasm Recurrence, LocalTriple Negative Breast NeoplasmsAdultAgedExome SequencingFemaleHumansMiddle AgedBiomarkers, Tumortriple negative breast cancertumor mutational burdenwhole exome sequencing

Identifiers

PMID37761830
PMCPMC10531222
OpenAlexW4386161619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.